US life sciences companies routinely sequence global filings on commercial intuition: New Drug Application (NDA) or Biologics License Application (BLA) to the FDA first, because Phase III data lands in the US format and the priority-review timelines are familiar; then Swissmedic, because Switzerland’s review windows are short and the pricing dynamics are favorable; then the EMA, because one authorization covers every Member State, though its review is the slowest. The EU Pharma Package’s final compromise text, published in consolidated Council form in early March 2026, implements the political agreement reached on 11 December 2025 in the trilogue, the closing negotiation between the European Parliament, the Council and the Commission. It embeds a hard 90-day window inside that sequence. Filing the EU marketing authorization application later than 90 days after any first non-Union filing forfeits a full year of EU market protection that would otherwise have been available, on conditions that turn out to have been fixed during pivotal-trial protocol design three to five years earlier. The analysis first sets out the new protection periods on which this Pharma Package series builds, then turns to the 90-day rule itself: what “first marketing authorisation application outside the Union” means under the new text, which co-conditions attach to the trigger, and how the rule changes the choice between filing first with Swissmedic or with the FDA, a choice sponsors have historically treated as separate from the EU filing.
1. The Centerpiece: The 8+1 Baseline, the Modular Bonuses, and the 11-Year Cap
The reform of the EU’s regulatory protection rules is the centerpiece of the EU Pharma Package, and US in-house counsel reading it for the first time will reach for the Hatch-Waxman framework as the closest US analogue. Under 21 U.S.C. § 355(j)(5)(F)(ii), new-chemical-entity (NCE) exclusivity runs for five years from FDA approval. A separate three years of new-clinical-investigation (NCI) exclusivity are available under 21 U.S.C. § 355(j)(5)(F)(iv) against an abbreviated new drug application for a change approved in a supplement supported by new clinical investigations essential to approval. That three-year clock attaches to each qualifying supplement and runs from the supplement’s own approval date; it does not stack onto the five-year NCE clock. Seven years apply under the Orphan Drug Act, narrowed on 3 February 2026 to the same approved use or indication within the rare disease or condition.121 U.S.C. § 355(j)(5)(F)(ii) (NCE exclusivity) and (F)(iv) (per-supplement NCI exclusivity); 21 U.S.C. § 360cc as amended by the Consolidated Appropriations Act, 2026, Pub. L. 119-75 (3 February 2026); FDA Draft Guidance on three-year NCI exclusivity (March 2026).
The European scheme is built differently. The analysis here is anchored to the final compromise text published in early March 2026 (ST-6367/26 for the revised Directive, ST-6366/26 for the companion Regulation) implementing the trilogue political agreement of 11 December 2025; it pre-dates Official Journal publication and the EMA scientific guidelines that several operative provisions envisage. Per the trilogue political agreement, the new baseline is eight years of regulatory data protection (during which no subsequent applicant may rely on the originator’s clinical data) plus one year of regulatory market protection (during which a subsequent application can be submitted and assessed but the product cannot reach the market), commonly referred to as the 8+1 baseline. Art. 80 of the Directive sets out both periods, although the published compromise text still shows deleted and inserted figures side by side.2Final compromise text for the revised Directive, Council doc ST-6367/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Art. 80–83; European Parliament press release (11 December 2025) confirming 8+1 baseline and 11-year combined cap.
Both clocks anchor to the initial marketing authorization under the global-marketing-authorization concept of Art. 5(2) of the Directive, which means that later additional therapeutic indications, new strengths, new pharmaceutical forms, new routes of administration, and other variations are all part of the same global MA and do not extend the underlying RDP clock; US in-house counsel used to Hatch-Waxman’s NCI exclusivity, which attaches to each supplement, should expect the EU rules to work the opposite way for line extensions. The EU’s 8+1 baseline alone gives nine years of protection. The US reaches eight years only when a supplement approved at year five adds its three-year NCI period, and that period protects only the supplemented change. At the optimized maximum, stacked prolongations take the EU period to the trilogue’s 11-year combined cap.
The reform is also not yet live. The Directive enters into force only on the twentieth day after Official Journal publication, and the new protection periods apply prospectively from a date of application that the final compromise text sets, in a bracketed placeholder, at twenty-four months after entry into force (an earlier eighteen-month figure is struck through). Under the transitional derogation in Art. 218(5) of the Directive, reference medicinal products whose marketing authorization application was submitted before that date remain subject to the data-protection periods of Art. 10 of Directive 2001/83/EC, the existing 8+2(+1) regime. The 90-day rule therefore governs the applications a sponsor will submit toward the end of the decade, not those in flight today; that is exactly why the comparator and sequencing decisions being made for products that will reach the EU under the new Art. 81 of the Directive are the ones that fix eligibility under it.
The Four Prolongation Paths and the Cap
Art. 81 of the Directive sits atop the baseline of Art. 80 of the Directive and provides for conditional 12-month prolongations of the regulatory market protection period. Here too the published Council document shows deleted and inserted wording side by side, but the agreed scheme can be worked out from the European Parliament’s press release and from law-firm commentary on the trilogue outcome published at the time.3Pharma Package Directive (n 2), Art. 81(2); EP press release of 11 December 2025; M Meulenbelt and others, ‘EU Pharma Package: Sharp New Tools With Limited Protections’ (Sidley Austin LLP, 18 December 2025), on the 8+1+1 scheme and the reading of the comparator limbs as alternative paths. The first prolongation, under Art. 81(2)(a) of the Directive, is conditioned on the applicant demonstrating at the time of the initial marketing authorization application that the medicinal product addresses an unmet medical need within the meaning of Art. 83 of the Directive; the compromise text strikes Art. 82 of the Directive, which in the Commission’s proposal tied that prolongation to release and continuous supply in every Member State where the authorization is valid. The second, under Art. 81(2)(b) of the Directive, requires for products containing a new active substance both that the clinical trials supporting the application used a relevant and evidence-based comparator agreed through EMA scientific advice and that the EU marketing authorization application was filed within 90 days of any first non-Union filing. The third, under Art. 81(2)(c) of the Directive, pairs the comparator condition with a multi-Member-State trial-design condition in lieu of the 90-day rule. A fourth, under Art. 81(2)(d) of the Directive, applies where the applicant has justified that a comparator is not possible or appropriate and combines the multi-Member-State and 90-day-filing conditions. Each individual prolongation adds 12 months. A separate 12-month prolongation under Art. 81(2a) of the Directive is available for new therapeutic indications that bring a significant clinical benefit in comparison with existing therapies, where authorization for the new indication is obtained during the regulatory data protection period; this prolongation may be granted only once. Art. 81(2b) of the Directive caps cumulative regulatory market protection at two years from RDP expiry, except where the supra-cap year of Art. 81(2a) of the Directive is added on top. The cap math is therefore determinative: a sponsor can claim at most one of the (a)/(b)/(c)/(d) bonus paths (any combination would exceed the two-year RMP cap), and can stack the new-indication bonus of Art. 81(2a) of the Directive above the cap, reaching the trilogue’s 11-year combined ceiling.4Pharma Package Directive (n 2), Art. 81(2b) (cumulative RMP cap of two years from RDP expiry) and Art. 81(2a) (supra-cap 12-month new-indication bonus); a separate Art. 80(4) suspension applies under Regulation (EU) 2025/2645 on compulsory licensing for crisis management.
The bonus is procedural, not substantive. It is captured or forfeited at the order-of-filing decision long before the EMA touches the dossier, and its co-conditions trace back to evidence-package design choices made three to five years earlier.
Three implications follow. First, capturing one of the (a)/(b)/(c)/(d) paths forecloses the other three, and only the new-indication bonus of Art. 81(2a) of the Directive can be added above the cap. Second, the prolongations are conditioned on facts the EMA can verify only after the fact (timing of the non-Union filing, the comparator used in the pivotal trials, the Member-State distribution of the clinical-trial sites, the unmet-medical-need profile of the indication); the applicant demonstrates them in its marketing authorization application rather than through a variation after authorization, and the bonus turns on that showing, not on the assessment committees’ view of the dossier’s substantive strength. Third, the conditions do not align with the trial-design timeline. Phase III comparator decisions are typically made three to five years before MAA submission; Member-State distribution of pivotal-trial sites is locked in at site activation; the EU-filing date is set at the end of the development program. The constraints run backwards along the development chain. A sponsor reaching the MAA-sequencing decision with a placebo-controlled US-anchored pivotal trial and no unmet-medical-need claim has already foreclosed every prolongation path under Art. 81(2) of the Directive.
2. The 90-Day Trigger: What “First MAA Outside the Union” Means in Practice
The text of the 90-day rule appears twice in Art. 81(2) of the Directive, first as Art. 81(2)(b)(ii) of the Directive and again as Art. 81(2)(d)(ii) of the Directive. Each instance uses the same wording: “the marketing authorisation application has been first submitted to the competent authority in the Union or has been submitted no later than 90 days after the submission of the application for the first marketing authorisation outside the Union”.5Pharma Package Directive (n 2), Art. 81(2)(b)(ii) and Art. 81(2)(d)(ii) (the 90-day filing condition; identical wording in both subparagraphs). For the new-active-substance products these bonuses reach, the Union filing is in practice the centralized application to the EMA, so “the competent authority in the Union” is the Agency rather than any national regulator. Three questions about the rule need answers before a US sponsor can model it against its actual filing patterns.
The first is what counts as “the application for the first marketing authorisation outside the Union”. The Directive does not define the phrase, and the obvious candidates are heterogeneous. A US New Drug Application or Biologics License Application is a national marketing authorization application filed with the FDA. A Swissmedic MAA filed under the HMG is, in EU-law terms, a third-country marketing authorization application; Switzerland is not a Member State and is not part of the European Economic Area. A UK MHRA Marketing Authorization Application post-Brexit is similarly extraterritorial. So are a Japan PMDA MAA, an Australian TGA submission and a Brazil ANVISA filing. The text contains no carve-out for any particular extraterritorial jurisdiction and no priority among them; the first submission anywhere outside the Union starts the clock. A US sponsor’s filing diary that has tracked “US-first” without distinguishing among non-EU jurisdictions will require recalibration before Art. 81 of the Directive applies.
The second is what counts as “submission”. The Directive uses “submitted” rather than the more elaborate “validated” or “accepted for filing”. For the EU clock, that wording suggests the date of submission to the relevant competent authority, not the date of validation. For the non-Union start of the clock, FDA NDA submission dates are tracked by FDA receipt; Swissmedic submission dates are recorded by Swissmedic’s eSubmission portal; the equivalent dates in other jurisdictions vary. Where a sponsor’s submission date and the regulator’s filing-receipt date differ for procedural reasons (a clarification request that returns the dossier to the sponsor, a procedural rejection that requires resubmission), the provision’s wording does not say which of the two starts the 90-day clock.
The third is the status of withdrawn or refused non-Union applications. The rule refers to “the application for the first marketing authorisation outside the Union”, in the singular and without modification. If a sponsor withdraws a US NDA after a Refuse-to-File determination and resubmits months later, did the first submission start the clock, or was it a procedural non-event? If the FDA issues a Complete Response Letter and the sponsor restarts the review cycle, does the 90-day clock still run from the original NDA submission? The Directive text does not address these scenarios, and the guidelines that Art. 81(3) of the Directive asks the Agency to set concern the criteria for proposing a comparator, not the filing clock.
There is a structural point that frames all three of the above. The 90-day requirement runs from submission to submission, not from approval to submission. A sponsor cannot game the rule by waiting for FDA approval before filing in the EU; the clock starts at FDA submission, regardless of how the FDA review eventually resolves. The traditional commercial logic of holding the EU dossier until the FDA approval signal has resolved is now structurally penalized at 12 months of EU market protection, on conditions that the sponsor will have already locked in years before the FDA approval signal even arrives. A parallel but distinct rule operates for priority antimicrobials under Art. 40(4)(c) of the Regulation, which uses a 180-day window rather than 90 days and which conditions the transferable data exclusivity voucher (TEV) rather than the prolongations of Art. 81(2) of the Directive.6Final compromise text for the revised Regulation, Council doc ST-6366/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Art. 40(4)(c) (180-day filing rule for priority-antimicrobial TEVs), Art. 41 (TEV transfer mechanics and EUR 490m blockbuster cap), Art. 19 (conditional MA framework). A reader who has seen the 180-day figure in industry commentary should not assume it governs the 90-day bonus discussed here; the two are structurally similar but distinct in scope and beneficiary, and how the TEV interacts with the 11-year cap is unresolved.
3. Comparative Clinical Trials and Multi-Member-State Trials as Co-Conditions
The 90-day filing rule never operates alone. In Art. 81(2)(b)(ii) of the Directive it is paired with the comparator condition in (b)(i); in Art. 81(2)(d)(ii) of the Directive it is paired with the multi-Member-State condition in (d)(i) and a justification that a comparator is not possible or appropriate. The third bonus that uses comparator design as a trigger, Art. 81(2)(c) of the Directive, pairs the comparator condition with the multi-Member-State condition without invoking the 90-day rule. That leaves three routes, each open only to medicinal products containing a new active substance: a comparator and the 90-day filing; a comparator and a multi-Member-State trial; or no comparator, a multi-Member-State trial and the 90-day filing. A sponsor unable to satisfy any of the three has no prolongation route under Art. 81(2) of the Directive open through the comparator family; the only bonus left under that paragraph is the unmet-medical-need bonus of point (a).
What counts as a “relevant and evidence-based comparator in accordance with the scientific advice provided by the Agency” is not defined in the Directive. Recital 52 of the Directive frames the bonus as an incentive for the inclusion of an evidence-based existing treatment as a comparator “in line with a scientific advice by the Agency”, intended to support subsequent health-technology assessment and pricing-and-reimbursement decisions by Member States.7Pharma Package Directive (n 2), Recitals 52 and 52a (comparative-clinical-evidence rationale and the EMA scientific-advice support role). Neither the Recital nor the condition itself asks the trials to show superiority or non-inferiority: Art. 81(2)(b)(i) and Art. 81(2)(c)(i) of the Directive make the use of such a comparator the condition and name no result the comparison must reach. The choice of comparator must accord with the EMA’s scientific advice, and Art. 81(3) of the Directive requires the Agency to set guidelines on the criteria for proposing a comparator. A sponsor that has not engaged EMA scientific advice on its Phase III comparator before MAA submission has no documentary basis on which to claim the (b) or (c) bonus, regardless of how strong the pivotal-trial comparator design is on its substantive merits.
The multi-Member-State condition is equally undefined in the Directive text. Art. 81(2)(c)(ii) and Art. 81(2)(d)(i) of the Directive refer to clinical trials “conducted in more than one Member State”, but beyond that floor of two Member States the text leaves the criterion open: how many subjects each Member State must contribute, how to treat a Member State whose participation was administrative rather than substantive, and how to treat one that joined the Union mid-trial. The EU Clinical Trials Regulation governs the conduct of such trials through the Clinical Trials Information System (CTIS) and has a reporting Member State coordinate the assessment of a trial run in several Member States, but it does not define a multi-Member-State trial for the purposes of the Pharma Package’s bonus; the Pharma Package introduces the concept without defining it, and the guidelines required by Art. 81(3) of the Directive concern the criteria for proposing a comparator, not this condition.8Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use [2014] OJ L158/1 (Clinical Trials Regulation, CTR), Art. 5 (reporting Member State coordination) and Art. 81 (CTIS).
The temporal asymmetry between the comparator-design decision and the bonus eligibility is the practical operating constraint. A pivotal-trial comparator is selected at the protocol-design stage, on the basis of regulatory advice received in the same window. A sponsor that designed a Phase III in 2024 or 2025 against the FDA’s preferred placebo-controlled or active-controlled standard, intending the same protocol to support the EU MAA, may discover at an MAA-sequencing decision taken after the new date of application that the FDA-preferred comparator does not satisfy the EU bonus condition because there is no contemporaneous EMA scientific-advice document supporting it. The protocol that satisfies the FDA does not, in that scenario, satisfy the bonus criterion; and the protocol cannot be reopened at MAA stage. A sponsor reaching the 90-day decision with a comparator design that pre-dates EMA engagement is reaching it with a closed door.
For the (b) path the two conditions are independent locks, set by different functions at different times: the comparator is fixed by clinical development at protocol design, the filing date by regulatory affairs at the end of the program. Satisfying one does nothing to preserve the other. A sponsor can hold a bonus-qualifying comparator and still forfeit (b) by missing the 90-day window, or hit the window with a comparator the Agency never agreed; only the program that has aligned both functions, set years apart, captures the bonus.
The operational lead time required to assemble the underlying EMA scientific-advice documentation is itself a binding constraint. The EMA’s Scientific Advice Working Party operates on roughly 70-day written-procedure cycles for standard requests; advice via discussion meeting extends the window to several months; the joint EMA-HTA scientific-advice procedure under the HTA Regulation framework requires earlier engagement and a longer cycle still. For a sponsor that has not started scientific advice on the comparator before locking the Phase III protocol synopsis, the documentation required to support the (b) or (c) prolongation cannot retroactively be assembled. The bonus under Art. 81(2) of the Directive and the HTA Joint Clinical Assessment (JCA) dossier built under the HTA Regulation call for the same comparator work: the JCA, which has applied to oncology and advanced-therapy medicinal products since 12 January 2025 and extends to orphan medicinal products in 2028 and to all centrally authorized products in 2030, requires comparator evidence aligned with health-technology-assessment-body expectations.9Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment [2021] OJ L458/1 (HTA Regulation), establishing the JCA mechanism for oncology and ATMPs from 12 January 2025. US sponsors building dossiers aligned to FDA preferences without parallel EMA and HTA engagement are foreclosing both the bonus eligibility under Art. 81(2) of the Directive and the JCA evidence package; sponsors investing in EMA scientific advice and HTA-aligned comparator design are simultaneously building both. The two requirements are operationally aligned but the alignment is invisible to a sponsor that treats them as separate workstreams.
4. Swiss Filing, FDA Filing, and the Sequence That Captures or Forfeits the Bonus
Three filing patterns dominate the global launch sequencing of US originators, and each interacts with the 90-day rule differently. The first is the FDA-first sequence: NDA or BLA to the FDA, then a Swissmedic MAA under the HMG after the FDA review converges on approval signals, then the EMA MAA after Swissmedic.10Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG) vom 15. Dezember 2000 (SR 812.21); Switzerland’s bilateral MRA with the EU covers GMP inspections but not MAA recognition. The second is the parallel-track sequence: simultaneous FDA and EMA filings. The third, often used for assets with a strong Swiss commercial profile, is the Swissmedic-first or Swissmedic-early sequence, which takes advantage of Swissmedic’s standard validation timeline and of Swiss pricing that is favorable relative to most EU Member States.
Under the pre-Pharma-Package regime, the choice between these patterns was substantively jurisdiction-independent for regulatory-protection purposes. Under the EU’s prior 8+2(+1) RDP scheme in Directive 2001/83/EC, the bonus year did not depend on filing sequence; it accrued, where it accrued, on the basis of new-therapeutic-indication evidence demonstrated at EMA assessment. Switzerland was a separate decision, governed by HMG commercial timing and the foreign-reference-pricing rules administered by BAG under the KVV framework. The new Art. 81(2)(b)(ii) and (d) of the revised Directive collapse those decisions: every Swissmedic, MHRA, FDA, PMDA, or other non-EU filing is, structurally, “outside the Union” for bonus purposes, and the first such filing starts the 90-day clock.
The Swissmedic-first scenario is the clearest illustration of the structural shift. Switzerland is not a Member State of the EU and is not part of the European Economic Area; the medicinal-products chapter of the bilateral Mutual Recognition Agreement between Switzerland and the EU provides for mutual recognition of Good Manufacturing Practice inspections but does not extend Swiss MAA filings into the EU regulatory perimeter. A Swissmedic MAA is therefore unambiguously “outside the Union” for the purposes of Art. 81(2)(b)(ii) of the Directive. For a US sponsor that files with Swissmedic in week 1 and reaches EU readiness only in week 30, on a straightforward reading of Art. 81(2)(b)(ii) and (d) of the revised Directive the EU filing falls outside the 90-day window and the (b) and (d) bonus paths would not be available; the guidelines envisaged by Art. 81(3) of the revised Directive concern comparator criteria, not the clock-start mechanics. A Swissmedic-early sponsor that files the EU marketing authorization application within 90 days of the Swiss submission keeps those paths open; it is the gap, not the Swiss-first sequence as such, that forfeits the bonus. Filing with Swissmedic first keeps its commercial advantages on the Swiss revenue side (faster review windows and the prospect of an authorized Swiss label that supports price negotiations with the BAG and foreign-reference-price positioning), but under the new rules it carries a 12-month EU exclusivity cost that did not exist before.
The FDA-First Sequence and Its Alternatives
The FDA-first sequence is the more common pattern and the more analytically interesting. A US sponsor’s NDA or BLA submission to the FDA starts the clock, and the EU application then has 90 days. The EU dossier must be substantively ready at FDA submission, not at FDA approval. The Common Technical Document modules submitted to the FDA overlap substantially with the EU MAA dossier, but the EU-specific modules (Module 1 in EU format, the EU summary of product characteristics, EU-specific risk-management plan content, environmental risk assessment documentation, Member-State-specific labeling) are non-trivial. A development program that has not parallelized EU-readiness work alongside the FDA-submission work has, in practice, no realistic prospect of meeting the 90-day window after FDA filing has occurred.
The parallel-track FDA-plus-EMA sequence is the structural workaround. If both applications are submitted on the same day, neither is “first” relative to the other in any meaningful sense, and the 90-day rule does not bite as between those two regulators; what then matters is the first non-Union filing in any other jurisdiction. This option, traditionally avoided by US sponsors for resource-allocation reasons (the EU dossier is large, the regulatory-affairs team is sized for sequential filings, and the FDA-review uncertainty argues against committing to the EU dossier before FDA signals are received), has a measurable value under the new rules, because it preserves the bonus. Whether that value, twelve months of EU market protection on a successful product, justifies the carrying cost of a fully EU-ready dossier six to twelve months earlier than the sponsor would otherwise have it is a deal-specific calculation that Art. 81 of the Directive pushes onto every US sponsor with an EU launch plan, not only those that had been considering parallel filings on commercial grounds. The carrying cost of standing EU-readiness amortizes across a multi-asset pipeline but falls on a single product for the one-asset biotech, so the operating-model investment tilts toward sponsors with several EU launches in view and against those with one.
Two further filing-sequence variables warrant brief mention. Japan PMDA submissions are also “outside the Union” for the purposes of Art. 81(2)(b)(ii) and (d) of the revised Directive; US sponsors with strong Asian commercial profiles in oncology and rare diseases, where a Japan-first or Japan-early sequence has historically supported price-anchoring against Japan’s NHI fee schedule, must apply the same 90-day clock starting at PMDA submission that the article’s Swiss-first analysis applies to Swissmedic. EMA PRIME designation, by contrast, operates inside the Union and does not trigger the clock; what PRIME does do is shorten the EMA’s review path and presuppose the kind of early EMA engagement that materially improves the operational feasibility of meeting a 90-day window after FDA submission. A US sponsor that has secured PRIME for an asset is structurally closer to bonus-path eligibility than one operating outside PRIME, even though PRIME itself confers no entitlement to the prolongation of Art. 81(2) of the Directive.
The bonus of Art. 81(2)(a) of the Directive no longer depends on supply. The compromise text strikes the launch condition that the Commission attached to it in Art. 82 of the Directive, together with Recital 56 and Recital 57 of the Directive on Member-State waivers of that condition, so a US sponsor whose commercial model cannot economically supply a Maltese or Estonian market in the absence of a meaningful tender can claim the (a) bonus without supplying that market. Supply pressure runs through Art. 56a of the Directive instead: a Member State may request launch within one year of the marketing authorization, and where supply does not follow within three years of the request, regulatory market protection lapses in that Member State. The cost of a skipped market is therefore no longer the (a) bonus across the Union but market protection in each Member State that makes a request.
5. Strategic Considerations for US Sponsors
The change Art. 81 of the Directive introduces is simple in form and far-reaching in practice. A sponsor whose comparator-design and Member-State-distribution decisions were taken during 2022 to 2024, before the Pharma Package’s final shape was visible at trilogue, now faces a question that was not on the table at protocol-design time: whether to re-sequence the global launch around the EU 90-day window where the upstream design choices still permit it, or to accept the forfeiture of a year of EU market protection that the bonus path under Art. 81(2)(b) or (d) of the Directive would, in principle, have made available. The bonus year is the tenth year after authorization (the new-indication year, where granted, is the eleventh), when revenue is at or near its peak and an extra twelve months of protected sales is close to pure margin. Whether to re-sequence or to forfeit is a board-level commercial decision, and the new rules have moved it earlier than the point at which US in-house counsel usually meet it.
Where a portfolio contains both bonus-eligible and bonus-ineligible assets, the calculus pulls in opposite directions. A comparator-design rare-disease asset with multi-Member-State pivotal trials may be a strong candidate for the (b) or (c) path; a placebo-controlled mass-market asset whose Phase III was finalized against FDA scientific advice without parallel EMA engagement may be a weaker candidate, and the question is whether the bonus on the eligible assets justifies a coordination overhead that affects portfolio-wide regulatory operations. The licensing implications are material: a development-stage out-licensing deal struck on the assumption of a bonus-captured EU exclusivity has different milestone economics than one struck assuming bonus forfeiture, and the M&A valuation of a development-stage asset whose pivotal-trial comparator is already locked is newly sensitive to a regulatory parameter that prior diligence frameworks have not surfaced. A buyer can detect that parameter in diligence but, once the pivotal trials are enrolled, can no longer cure it. A separate calculus applies where an asset qualifies for the unmet-medical-need bonus of Art. 81(2)(a) of the Directive: under the two-year RMP cap of Art. 81(2b) of the Directive, capturing the (a) bonus consumes the sponsor’s ability to also capture any of the comparator-themed (b), (c), or (d) bonuses, since the (a) limb fills the same one-year-of-extension slot that (b)/(c)/(d) would otherwise fill. For those assets the 90-day filing rule’s strategic salience drops sharply; the sequencing question instead focuses on demonstrating the unmet medical need in the initial application, on the launch requests that Art. 56a of the Directive allows Member States to make, and on the new-indication bonus of Art. 81(2a) of the Directive that remains stackable above the cap.
The Conditional-Authorization Cliff
A different strategic question presents itself where a US sponsor anticipates entering the EU through the Pharma Package’s conditional-marketing-authorization pathway, which EMA’s PRIME designation routinely funnels assets into. Art. 81(2) of the Directive carries a specific carve-out for conditional MAs granted under Art. 19 of the companion Regulation: the (a) prolongation will only attach if the conditional MA is converted to a full marketing authorization under Art. 19(7) of the Regulation within four years of the conditional grant, and (for products invoking the unmet-medical-need limb of Art. 83(1)(b) of the Directive) the post-authorization studies referenced in Art. 19(4) of the Regulation must include clinical trials that use, where possible and appropriate, a relevant and evidence-based comparator.11Pharma Package Directive (n 2), Art. 81(2) end-subparagraph (conditional-MA carve-out), with Art. 19, Art. 19(4) and Art. 19(7) of the companion Pharma Package Regulation (n 6). The cliff is operational: a sponsor relying on the conditional pathway to reach EU patients quickly under PRIME must also commit, at conditional grant, to a confirmatory study program that closes within four years and (where the unmet-need limb is invoked) carries the comparator design the post-grant cleanup will demand. US sponsors that have not historically planned confirmatory studies on a four-year clock will discover the cliff at conversion, when the (a) bonus is structurally lost rather than negotiable.
The analysis above concerns the RDP and RMP periods that govern non-orphan medicinal products. Orphan-designated assets, which represent a substantial fraction of US biotech’s most valuable pipelines, sit on a different protection track entirely. Under the Pharma Package’s orphan provisions, protection takes the form of a market exclusivity of nine years for standard orphan medicinal products and eleven years for “breakthrough” orphan medicinal products addressing a disease for which no medicinal product is authorized in the Union, granted per product rather than per indication.12Pharma Package Regulation (n 6), Chapter VI, Art. 63 ff., establishing the orphan-designation framework, the breakthrough qualification at Art. 70, and the market-exclusivity periods at Art. 71. The 90-day filing rule discussed in this article does not condition the orphan exclusivity period, although the underlying filing-sequence question (FDA-first, Swissmedic-first, parallel, EMA-first) does interact with the orphan-track approval timing. US biotechs with orphan-designated lead assets should treat the analysis here as the framework that applies to their non-orphan portfolio segments and to indication expansions that fall outside the orphan designation.
The commercial case for Swissmedic-first filing sits uneasily with the new rules. Sponsors with strong Swiss commercial profiles, where Switzerland’s BAG SL listing and pricing economics produce revenue acceleration, have historically treated Swissmedic-first as value-creating independent of EMA timing. Whether that calculation still holds turns on whether the Swiss revenue acceleration between Swissmedic and EMA approval compensates for the 12 months of EU market protection structurally forfeited a decade later, a question that depends on product trajectory, EU pricing under the simultaneous access-conditionality reforms, and discount-rate treatment of cash flows separated by years. There is no general answer.
The deepest question may be the retroactive one. At what point does an evidence-package decision made years earlier become the binding constraint on the sponsor’s ability to capture the bonus at all? For pivotal trials already enrolled and approaching readout, the comparator design is fixed. For trials in protocol design at the time of this article’s publication, the comparator decision is the one still to be made, and the regulatory-affairs and commercial teams need to agree on it well before the protocol synopsis is finalized. For programs still in Phase II planning, the choice is between designing the pivotal trial around the bonus criteria from the outset, accepting the cost of EMA scientific advice and the comparator constraints, or designing the protocol around the FDA approval timeline and accepting that the path of Art. 81(2) of the Directive is closed on the EU side. Whether the bonus can be captured is now decided upstream of the regulatory team, inside the commercial development plan, where US in-house counsel without an EU or Swiss legal team typically do not meet EU regulatory questions at all until the bonus has already been lost.